Adora2b activation inhibits DC migration, preventing them from escaping the immunosuppressive TME to initiate anti-tumor responses and prevents them from initiating the CD8+ T-cell and Th1 immune response, suppressing anti-tumor immunity. This evidence concerns the gene CD8A and neoplasm.